References
1. Asatryan M.N., Gerasimuk E.R., Lagunov D.Yu., Semenenko T.A., Ginzburg A.L. Forecasting the dynamics of the incidence of CAVID-19 and planning measures for vaccination of the population of Moscow on the basis of mathematical modeling. Zhurnal mikrobiologii, èpidemiologii i immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2020; 97 (4): 289–302. DOI: https://doi.org/10.36233/0372-9311-2020-97-4-1
2. Pollán M., Pérez-Gómez B., Pastor-Barriuso R., Oteo J., et al. Prevalence of SARSCoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; 396 (10250): 535–44. DOI: http://doi.org/10.1016/S0140-6736(20)31483-5
3. The official Internet resource for informing the population about coronavirus (COVID-19). Stopcoronavirus.rf. 2021. https://стопкоронавирус.рф/about-covid/ (date of acess June 13, 2021). (in Russian)
4. Yushchuk N.D., Vengerov Yu.A., eds. Infectious diseases: national guidelines. Moscow: GEOTAR-Media; 2009: 1056. (Series “National guides”) (in Russian)
5. Briko N.I., Tsapkova N.N., Batyrshina L.R., Korshunov V.A., et al. Problems of vaccination prevention of the adult population. Èpidemiologiâ i vakcinoprofilaktika [Epidemiology and Vaccinal Prevention]. 2018; 17 (2): 4–15. DOI: https://doi.org/10.31631/2073-3046-2018-17-2-4-15 (in Russian)
6. Briko N.I., Mindlina A.Ya., Polibin R.V., Galina N.P., et al. Assessment of the attitude to immunoprophylaxis of various population groups of the Russian Federation. Zhurnal mikrobiologii [Journal of Microbiology]. 2017; (2): 98–103. DOI: https://doi.org/10.36233/0372-9311-2017-2-98-103 (in Russian)
7. Sheikh A., McMenamin J., Taylor B., Robertson C., et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397 (10293): 2461–2. DOI: https://doi.org/10.1016/S0140-6736(21)01358-1
8. Danilov A.N., Eremin V.I., Abramyan T.L., Mamonova I.A., et al. Mortality from COVID-19 among people with HIV infection in the Saratov region. Žurnal infektologii [Journal of Infectology]. Appendix 1. 2021; 13 (3): 133. (in Russian)
9. Letter of the Ministry of Healthcare of the Russian Federation dated January 21, 2021 No. 1/4/1-333 “On the procedure for vaccination with the GAM-COVID-VAC vaccine against COVID-19 of the adult population”. (in Russian)
10. Order of the Ministry of Healthcare of the Russian Federation No. 47n dated 03.02.2021 “On Amendments to the calendar of preventive vaccinations for epidemic indications, approved by Order of the Ministry of Health of the Russian Federation No. 125n dated March 21, 2014”. (in Russian)
11. Decree of the Government of the Saratov Region dated June 16, 2021 No. 456-P “On Amendments to the Decree of the Government of the Saratov Region dated March 26, 2020 No. 208-P “On the introduction of restrictive measures in connection with the threat of the spread of coronavirus infection (COVID-19)”. (in Russian)
12. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397 (10275): 671–81. DOI: https://doi.org/10.1016/S0140-6736(21)00234-8
13. Petrov V.I., Gerasimenko A.S., Gorbatenko V.S., Shatalova O.V., Ponomareva A.V. Efficacy and safety of vaccines for the prevention of COVID-19. Lekarstvennyy vestnik [Medicinal Bulletin]. 2021; 15 (2): 3–7. (in Russian)
14. Ryzhikov A.B., Ryzhikov E.A., Bogryantseva M.P., et al. A simple blind placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the EpiVacCorona vaccine for the prevention of COVID-19 on volunteers aged 18–60 years (phase I–II). Infektsiya i immunitet [Russian Journal of Infection and Immunity]. 2021; 11 (2): 283–96. (in Russian). DOI: https://doi.org/10.15789/2220-7619-ASB-1699
15. Temporary methodological recommendations “Procedure for vaccination of the adult population against COVID-19”; 2021. (in Russian)
16. Singanayagam A., Hakki S., Dunning J., Madon K.J., et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2022; 22 (2): 183–95. DOI: https://doi.org/10.1016/S1473-3099(21)00648-4